🚀 VC round data is live in beta, check it out!
Definium Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Definium Therapeutics and similar public comparables like ANI Pharmaceuticals, Zhejiang Jolly, RAPT Therapeutics, Innoviva and more.
Definium Therapeutics Overview
About Definium Therapeutics
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Founded
2010
HQ
Employees
74
Website
Sectors
Financials (LTM)
EV
$2B
Definium Therapeutics Financials
Definium Therapeutics reported last 12-month revenue of — and negative EBITDA of ($181M).
In the same LTM period, Definium Therapeutics generated — in gross profit, ($181M) in EBITDA losses, and had net loss of ($189M).
Definium Therapeutics P&L
In the most recent fiscal year, Definium Therapeutics reported revenue of — and EBITDA of ($166M).
Definium Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($181M) | XXX | ($166M) | XXX | XXX | XXX |
| Net Profit | ($189M) | XXX | ($184M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Definium Therapeutics Stock Performance
Definium Therapeutics has current market cap of $2B, and enterprise value of $2B.
Definium Therapeutics' stock price is $17.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-1.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDefinium Therapeutics Valuation Multiples
Definium Therapeutics trades at (8.4x) EV/EBITDA.
Definium Therapeutics Financial Valuation Multiples
As of March 29, 2026, Definium Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Definium Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Definium Therapeutics has a P/E ratio of (8.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (8.4x) | XXX | (9.2x) | XXX | XXX | XXX |
| EV/EBIT | (8.6x) | XXX | (9.2x) | XXX | XXX | XXX |
| P/E | (8.9x) | XXX | (9.2x) | XXX | XXX | XXX |
| EV/FCF | (9.8x) | XXX | (11.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Definium Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Definium Therapeutics Margins & Growth Rates
Definium Therapeutics' revenue in the last fiscal year grew by —.
Definium Therapeutics' revenue per employee in the last FY averaged $0.0M.
Definium Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 23% | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Definium Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Jolly | XXX | XXX | XXX | XXX | XXX | XXX |
| RAPT Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Innoviva | XXX | XXX | XXX | XXX | XXX | XXX |
| AnaptysBio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Definium Therapeutics M&A Activity
Definium Therapeutics acquired XXX companies to date.
Last acquisition by Definium Therapeutics was on XXXXXXXX, XXXXX. Definium Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Definium Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDefinium Therapeutics Investment Activity
Definium Therapeutics invested in XXX companies to date.
Definium Therapeutics made its latest investment on XXXXXXXX, XXXXX. Definium Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Definium Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Definium Therapeutics
| When was Definium Therapeutics founded? | Definium Therapeutics was founded in 2010. |
| Where is Definium Therapeutics headquartered? | Definium Therapeutics is headquartered in United States. |
| How many employees does Definium Therapeutics have? | As of today, Definium Therapeutics has over 74 employees. |
| Is Definium Therapeutics publicly listed? | Yes, Definium Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Definium Therapeutics? | Definium Therapeutics trades under DFTX ticker. |
| When did Definium Therapeutics go public? | Definium Therapeutics went public in 2020. |
| Who are competitors of Definium Therapeutics? | Definium Therapeutics main competitors are ANI Pharmaceuticals, Zhejiang Jolly, RAPT Therapeutics, Innoviva. |
| What is the current market cap of Definium Therapeutics? | Definium Therapeutics' current market cap is $2B. |
| Is Definium Therapeutics profitable? | No, Definium Therapeutics is not profitable. |
| What is the current EBITDA of Definium Therapeutics? | Definium Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Definium Therapeutics? | Current EBITDA multiple of Definium Therapeutics is (8.4x). |
| What is the current FCF of Definium Therapeutics? | Definium Therapeutics' last 12 months FCF is ($155M). |
| What is the current EV/FCF multiple of Definium Therapeutics? | Current FCF multiple of Definium Therapeutics is (9.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.